Creating targeted T cells to treat acute myeloid leukemia
Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11121382
This study is testing a new treatment for acute myeloid leukemia (AML) that uses specially designed immune cells to target a unique protein found only on AML cells, aiming to make the therapy safer and more effective for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11121382 on ClinicalTrials.gov |
What this research studies
This research focuses on developing chimeric antigen receptor T cells that specifically target a unique protein found on the surface of acute myeloid leukemia (AML) cells. By identifying the U5 snRNP200 protein, which is present on AML cells but absent from normal blood cells, the researchers aim to create a more effective immunotherapy for patients with AML. The approach involves engineering T cells to recognize and attack these cancer cells, potentially leading to improved treatment outcomes. Patients may be involved in trials to assess the safety and effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have not responded well to existing treatments.
Not a fit: Patients with other types of leukemia or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective immunotherapy option for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promise in using targeted T cell therapies for other cancers, indicating potential success for this novel approach in AML.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DANIYAN, ANTHONY — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: DANIYAN, ANTHONY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.